| 2025 | 2024 | |||
|---|---|---|---|---|
| Gross margin | -2,1 M € | -259.2% | -590,5 k € | |
| EBITDA | -2,4 M € | -187.4% | -843,3 k € | |
| Operating profit | -2,7 M € | -150.0% | -1,1 M € | |
| Profit/loss | -2,7 M € | -146.5% | -1,1 M € | |
| Equity | 2,2 M € | -42.0% | 3,8 M € | |
| Total assets | 5,3 M € | +3.8% | 5,1 M € | |
| Cash | 1,9 M € | +27.6% | 1,5 M € | |
| Debts | 2,7 M € | +678.1% | 342,2 k € | |
| Staff | 4,3 | 2,6 | ||
Source: Belgian Official Gazette
Private limited company · Gent · incorporated on 29/06/2023 · 4,3 ETP
Private limited company loss-making in the latest fiscal year. Cash position rising (+27.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
Obulytix is a Private limited company incorporated in 2023. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Gent. It employs on average 4,3 ETP workers (FTE).